Press Releases

Key Players in the Spinal Cord Injury Treatment Market

Growth and Forecast of the Spinal Cord Injury Treatment Market

The spinal cord injury treatment market was valued at USD 7.13 billion in 2023 and is expected to grow to USD 11.00 billion by 2032. This growth is projected at a compound annual growth rate (CAGR) of 4.8% from 2024 to 2032.

Report Highlights:

  • Complete spinal cord injuries held the largest market share in 2023, accounting for 60%.
  • Corticosteroids made up 40% of the market share in 2023.
  • Hospitals were the leading contributors to the market, holding 60% of the share in 2023.
  • Every year, approximately 18,000 new spinal cord injuries are reported in the United States, based on an annual incidence rate of 54 cases per million people. The high number of individuals living with spinal cord injuries underscores the ongoing need for prevention and treatment efforts.

A spinal cord injury occurs when the bundle of nerves in the spine is damaged, which can lead to changes in sensation, movement, and strength below the injury site. This injury can result from direct trauma or damage to the bones around the spine. Symptoms vary depending on the severity and location of the injury. Injuries higher up on the spine can affect larger areas of the body, potentially causing paralysis, while injuries lower on the spine may only affect the legs.

Common symptoms of spinal cord injuries include numbness, tingling, or loss of sensation in the hands and feet, as well as paralysis, pain, or pressure in the head, neck, or back. Other symptoms may include weakness, difficulty walking, breathing problems, and changes in sexual function. In the U.S., motor vehicle accidents and serious falls are the leading causes of spinal cord injuries, followed by violence, sports injuries, medical accidents, and other incidents. Age, alcohol use, certain medical conditions, and failure to use appropriate safety measures like seat belts or sports equipment can increase the risk of spinal cord injury.

Older individuals are more prone to spinal cord injuries due to age-related changes in the spine, such as degenerative disc disease. With the global population aging, the incidence of spinal cord injuries is expected to rise, emphasizing the growing need for spinal implants and devices.

According to the National Spinal Cord Injury Association, about 282,000 people in the U.S. are living with spinal cord injuries, and around 17,000 new cases are diagnosed annually. These numbers highlight the increasing demand for specialized treatments and interventions to support individuals with spinal cord injuries.

Companies in the Spinal Cord Injury Treatment Market

  • Acorda Therapeutics, Inc.
  • Asterias Biotherapeutics
  • ReNetX Bio
  • BioArctic AB
  • BioTime, Inc.
  • InVivo Therapeutics
  • Kringle Pharma, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Pharmicell Co. Ltd.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/spinal-cord-injury-treatment-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5143

We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

 

Elena Morales

Elena Morales is a healthcare industry expert working at Healthcare Web Wire Consulting Firm, a subsidiary of Towards Healthcare. With her excellent knowledge of the field, Elena helps clients optimize their operations and navigate healthcare regulations. She's dedicated to staying updated on industry trends to make a positive impact on patient care. Elena is known for her professionalism and commitment to excellence, making her a valuable asset to any team.

Recent Posts

Kedrion Biopharma’s COAGADEX® Receives FDA Orphan Drug Designation for Acquired Factor X Deficiency (AFXD)

Kedrion Biopharma has announced that its human coagulation factor X concentrate, COAGADEX®, has been granted orphan drug designation by the… Read More

2 days ago

Benecard PBF and DecisionRX Join Forces to Personalize and Optimize Pharmacy Benefits

enecard PBF, a pioneer in pharmacy benefit facilitation, has announced a strategic partnership with DecisionRX, Inc., a leader in medication… Read More

2 days ago

Four Resilient Biotech Companies Making Waves in a Challenging Market

In a high-stakes biotech industry where drug development can span over a decade, four small but determined biotech companies are… Read More

2 days ago

Natera Launches TEODOR Trial in Partnership with ABCSG to Advance Personalized Breast Cancer Treatment

cell-free DNA and precision medicine, has officially announced the launch of the TEODOR trial (ABCSG 61), a groundbreaking phase 2,… Read More

2 days ago

Interventional Radiology Market: Size, Growth, and Leading Companies Driving Innovation

The global interventional radiology market is witnessing rapid expansion, driven by advancements in minimally invasive procedures, rising demand for diagnostic… Read More

2 days ago

Physical Therapy Market Growth and Leading Companies Driving Innovation

The global physical therapy market is valued at USD 28.06 billion in 2024, growing to USD 29.18 billion in 2025… Read More

2 days ago